Literature DB >> 28785443

Metabolic Therapy in Heart Failure.

Yury Lopatin1.   

Abstract

Metabolic impairments play an important role in the development and progression of heart failure. The use of metabolic modulators, the number of which is steadily increasing, may be particularly effective in the treatment of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. This review focuses on the role of metabolic modulators, in particular trimetazidine, as a potential additional medication to conventional medical therapy in heart failure.

Entities:  

Keywords:  Heart failure; cardiac metabolism; metabolic therapy; trimetazidine

Year:  2015        PMID： 28785443      PMCID： PMC5490953          DOI： 10.15420/cfr.2015.1.2.112

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN： 2057-7540


  60 in total

1.  Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery.

Authors:  Kyoung-Ha Park; Woo Jung Park; Min-Kyu Kim; Duk-Woo Park; Jae-Hyeong Park; Hyun-Sook Kim; Goo-Yeong Cho
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  [Chinese guidelines for the diagnosis and treatment of heart failure 2014].

Authors: 
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2014-02

3.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

4.  Trimetazidine shortens QTc interval in patients with ischemic heart failure.

Authors:  Gregor Zemljic; Matjaz Bunc; Bojan Vrtovec
Journal:  J Cardiovasc Pharmacol Ther       Date:  2009-12-04       Impact factor: 2.457

5.  The effects of trimetazidine on heart rate variability in patients with heart failure.

Authors:  Yilmaz Gunes; Unal Guntekin; Mustafa Tuncer; Musa Sahin
Journal:  Arq Bras Cardiol       Date:  2009-08       Impact factor: 2.000

Review 6.  Targeting mitochondrial oxidative metabolism as an approach to treat heart failure.

Authors:  Natasha Fillmore; Gary D Lopaschuk
Journal:  Biochim Biophys Acta       Date:  2012-08-31

7.  Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Authors:  Leong Lee; Ross Campbell; Michaela Scheuermann-Freestone; Rachel Taylor; Prasad Gunaruwan; Lynne Williams; Houman Ashrafian; John Horowitz; Alan G Fraser; Kieran Clarke; Michael Frenneaux
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

Review 8.  Cardiovascular remodelling in coronary artery disease and heart failure.

Authors:  Gerd Heusch; Peter Libby; Bernard Gersh; Derek Yellon; Michael Böhm; Gary Lopaschuk; Lionel Opie
Journal:  Lancet       Date:  2014-05-13       Impact factor: 79.321

9.  Ranolazine preserves and improves left ventricular ejection fraction and autonomic measures when added to guideline-driven therapy in chronic heart failure.

Authors:  Gary L Murray; Joseph Colombo
Journal:  Heart Int       Date:  2014-12-22

10.  Ranolazine improves autonomic balance in heart failure when added to guideline-driven therapy.

Authors:  Gary L Murray; Joseph Colombo
Journal:  Heart Int       Date:  2014-09-23
View more
  8 in total

Review 1.  Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation.

Authors:  Alan J Mouton; Xuan Li; Michael E Hall; John E Hall
Journal:  Circ Res       Date:  2020-03-12       Impact factor: 17.367

Review 2.  Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair.

Authors:  William P Lafuse; Daniel J Wozniak; Murugesan V S Rajaram
Journal:  Cells       Date:  2020-12-31       Impact factor: 6.600

Review 3.  Metabolic Modulation of Cardiac Metabolism in Heart Failure.

Authors:  Giuseppe Mc Rosano; Cristiana Vitale
Journal:  Card Fail Rev       Date:  2018-08

4.  Angina due to coronary artery disease with left ventricular systolic dysfunction.

Authors:  Yury Lopatin
Journal:  Eur Heart J Suppl       Date:  2019-11-12       Impact factor: 1.803

5.  Shenmai Injection Improves Energy Metabolism in Patients With Heart Failure: A Randomized Controlled Trial.

Authors:  Shao-Mei Wang; Li-Fang Ye; Li-Hong Wang
Journal:  Front Pharmacol       Date:  2020-04-17       Impact factor: 5.810

6.  Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion.

Authors:  Hina L Nizami; Parmeshwar B Katare; Pankaj Prabhakar; Ramu Adela; Soumalya Sarkar; Sudheer Arava; Praloy Chakraborty; Subir K Maulik; Sanjay K Banerjee
Journal:  Oxid Med Cell Longev       Date:  2022-06-11       Impact factor: 7.310

7.  The Cardio- and Neuroprotective Effects of Corvitin and 2-Oxoglutarate in Rats with Pituitrin-Isoproterenol-Induced Myocardial Damage.

Authors:  V Tkachenko; Y Kovalchuk; N Bondarenko; О Bondarenko; G Ushakova; A Shevtsova
Journal:  Biochem Res Int       Date:  2018-09-03

Review 8.  Heart Failure and Drug Therapies: A Metabolic Review.

Authors:  Frank Yu; Bianca McLean; Mitesh Badiwala; Filio Billia
Journal:  Int J Mol Sci       Date:  2022-03-09       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.